Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25399648 | 0.94 | ADAM17 (0.41) | ADAM17ALDH1A1 | |
| SCHEMBL25399531 | 0.91 | EGLN1 (0.40) | TACR1TACR3ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL25400660 | 0.90 | NR4A2 (0.36) | TACR1TACR3HSD17B10 | |
| SCHEMBL25402654 | 0.90 | EGLN1 (0.41) | ADAM17TSHRCYP2C9CYP2C19 | |
| SCHEMBL25401115 | 0.90 | HCAR2 (0.38) | ADAM17TACR1TACR3CYP2C9CYP2C19 | |
| SCHEMBL25398914 | 0.90 | EGLN1 (0.39) | TACR1ALDH1A1MAPT | |
| SCHEMBL25401329 | 0.88 | POLB (0.38) | ADAM17TSHRALDH1A1MAPTALOX15 | |
| SCHEMBL25399422 | 0.88 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL25400368 | 0.87 | ADAM17 (0.44) | ADAM17ALDH1A1SMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL25061660 | 0.86 | TACR1 (0.38) | ADAM17TACR1TACR3TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | ADAM17 4639/4885TACR1 4151/4885TACR3 4210/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | ADAM17 3074/4885TACR1 4707/4885TACR3 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.